Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.64 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | TDO2 | P48775 | 1/20 | 0.54 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426063 | 0.89 | INSR (0.54) | PTK2PTK2BROCK2ROCK1IDO1 | |
| SCHEMBL6259622 | 0.84 | PTK2 (0.67) | PTK2PTK2BROCK2ROCK1JAK2 | |
| SCHEMBL6213528 | 0.81 | PTK2 (0.78) | PTK2PTK2BROCK2ROCK1JAK2 | |
| SCHEMBL6212988 | 0.81 | PTK2 (0.75) | PTK2PTK2BIDO1TDO2 | |
| SCHEMBL6209907 | 0.81 | PTK2 (0.75) | PTK2PTK2BROCK2ROCK1TRPM5 | |
| SCHEMBL6241400 | 0.81 | PTK2 (0.75) | PTK2PTK2BROCK1JAK2 | |
| SCHEMBL6257378 | 0.79 | PTK2 (1.00) | PTK2PTK2BROCK2 | |
| SCHEMBL13220366 | 0.78 | PTK2 (0.60) | PTK2PTK2BROCK2ROCK1JAK2 | |
| SCHEMBL7256998 | 0.78 | JAK2 (0.56) | PTK2PTK2BROCK2ROCK1MAOB | |
| SCHEMBL5424050 | 0.77 | TRPM5 (0.50) | ROCK2ROCK1TRPM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | PTK2 423/4885PTK2B 76/4885ROCK2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.